Combination chemotherapy for advanced non-Hodgkin's lymphoma of unfavourable histology

Thirty previously untreated adults with diffuse histiocytic and diffuse undifferentiated lymphoma were treated with a combination of adriamycin, vincristine, prednisolone, and L-asparaginase. Complete remission was achieved in 11 out of 12 cases with stage III and 7 out of 18 cases with stage IV dis...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1978, Vol.1 (2), p.107-112
Main Authors: Lister, T A, Cullen, M H, Brearley, R B, Beard, M E, Stansfeld, A G, Whitehouse, J M, Wrigley, P F, Ford, J M, Malpas, J S, Crowther, D
Format: Article
Language:English
Subjects:
Adolescent
Adult
Asparaginase - therapeutic use
Clinical Trials as Topic
Doxorubicin - therapeutic use
Drug Therapy, Combination
Female
Humans
Lymphoma - drug therapy
Lymphoma - pathology
Lymphoma - radiotherapy
Male
Middle Aged
Neoplasm Staging
Prednisolone - therapeutic use
Prognosis
Time Factors
Vincristine - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thirty previously untreated adults with diffuse histiocytic and diffuse undifferentiated lymphoma were treated with a combination of adriamycin, vincristine, prednisolone, and L-asparaginase. Complete remission was achieved in 11 out of 12 cases with stage III and 7 out of 18 cases with stage IV disease (P less than 0.005). Bone marrow infiltration, clinical central nervous system involvement, and massive intra-abdominal disease all influenced the prognosis adversely. Complete remission was followed by cranial irradiation and intrathecal methotrexate, and maintained with weekly cyclophosphamide and methotrexate and daily 6-mercaptopurine. The duration of remission was significantly longer for patients with stage III disease (the median of which has not been reached), than for patients with stage IV disease (P = 0.007). Survival was significantly longer for patients in whom complete remission was achieved than for those in whom it was not (P = 0.001), and also for patients with stage III than for those with stage IV disease (P = 0.02).
ISSN:0344-5704
1432-0843
DOI:10.1007/BF00254044